Skip to main content

Table 3 Analysis of factors correlated with urinary glucose changes at day 7 of SGLT2 inhibitor treatment

From: Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

  ΔUrinary glucose p value
ΔMBG 0.239 0.272
ΔSD −0.468* 0.024
ΔCV −0.654** 0.001
ΔTime at >140 mg/dL 0.352 0.100
ΔTime at <70 mg/dL −0.277 0.201
ΔTime at 70–140 mg/dL −0.314 0.144
ΔMAGE −0.520* 0.011
ΔLAGE −0.465* 0.025
ΔM value 0.103 0.640
ΔMPPGE −0.436* 0.038
ΔMax −0.027 0.904
ΔMin 0.418* 0.047
  1. Data are results of Pearson correlation analysis of variables with normal distribution (ΔSD, ΔCV, ΔTime at >140 mg/dL, ΔTime at 70–140 mg/dL, ΔMAGE, ΔLAGE, ΔMMPGE and ΔMax) and Spearman rank correlation for variables with skewed distribution
  2. IRI Immunoreactive insulin, HbA1c glycated hemoglobin, CPR C peptide immunoreactivity, eGFR estimated glomerular filtration rate, CGM continuous glucose monitoring, SGLT2-I sodium glucose cotransporter 2 inhibitor, MBG mean blood glucose, SD standard deviation, CV coefficient of variation, MAGE mean amplitude of glycemic excursions, LAGE largest amplitude of glycemic excursions, MPPGE mean postprandial glucose excursions, BG blood glucose, BB before breakfast, AB after breakfast, BL before lunch, AL after lunch, BD before dinner, AD after dinner
  3. * p < 0.05, ** p < 0.01